Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Generic Industry Consolidation Illustrated In ANDA Holder List

Executive Summary

Most of US FDA's approved ANDAs are owned by a handful of firms, while the vast majority of owners have between one and five.

Advertisement

Related Content

GDUFA II: More Than 2,000 ANDAs Remain Unclaimed, Large Firms Still Dominate
ANDA Holder Fee Will Start With Industry-Driven Database 'Clean-Up'
Generic Drug User Fees Will Jump More Than 50% In FY 2018
GDUFA II: ANDAs, Not Facilities Will Govern Revenue
ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal
GDUFA II Will Include Small Business Relief, Priority ANDA Reviews
Teva, Allergan Generics: FTC Worried About A Multitude Of Markets, Not A Behemoth
GDUFA II: Facility Fees Might Be Deferred Until ANDA Approval
Big paydays ahead as Actavis buys Allergan for $219/share

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS119711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel